STAT3 and hepatocellular carcinoma: This study is the first time demonstrating the potential molecular mechanism underlying the effects of CKS1B on the activation of the JAK/STAT3 signaling pathway, complementing the evidence and molecular pathways for CKS1B or the JAK/STAT3 pathway as a therapeutic target for HCC.